The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials
Abstract
Purpose: Patient-reported outcomes (PROs), routinely collected as a part of cancer clinical trials, have been linked with survival in numerous clinical studies, but a comprehensive critical review has not been reported. This study systematically assessed the impact of PROs on patient survival after a cancer diagnosis within the context of clinical trials. Design: Cancer clinical trials that assessed baseline PROs and mortality were identified through MEDLINE (through December 2006) supplemented by the Cochrane database, American Society of Clinical Oncology/European Society for Medical Oncology abstracts and hand searches. Inclusion criteria were publication in English language and use of multivariate analyses of PROs that controlled for one or more clinical factors. Two raters reviewed each study, abstracted data, and assessed study quality; two additional raters verified abstractions. Results: In 36 of 39 studies (N = 13,874), at least one PRO was significantly associated with survival (P < .05) in multivariate analysis, with varying effect sizes. Studies of lung (n = 12) and breast cancer (n = 8) were most prevalent. The most commonly assessed PRO was quality of life, measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 in 56% of studies. Clinical variables adjusted for included performance status (PS), treatment arm, stage, weight loss, and serum markers. Results indicated that PROs provide distinct prognostic information beyond standard clinical measures in cancer clinical trials. Conclusion: PROs might be considered for stratification purposes in future trials, as they were often better predictors of survival than PS. Studies are needed to determine whether interventions that improve PROs also increase survival and to identify explanatory mechanisms through which PROs relate to survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EFFECT OF PSYCHOSOCIAL TREATMENT ON SURVIVAL OF PATIENTS WITH METASTATIC BREAST CANCER
Spiegel, D., Kraemer, H., Bloom, J., & Gottheil, E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91551-1 · Cited by 2,353
Quality of life and pharmacoeconomics in clinical trials
Spilker, B. (1996) · DigitalGeorgetown (Georgetown University Library) · Cited by 1,862
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
Sprangers, M. A. G., & Aaronson, N. K. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90052-o · Cited by 1,081
The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer
Goodwin, P. J., Leszcz, M., Ennis, M., Koopmans, J., Vincent, L., Guther, H., Drysdale, E., Hundleby, M., Chochinov, H. M., Navarro, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011871 · Cited by 891
Mapes, D. L., Lopes, A. A., Satayathum, S., Mccullough, K. P., Goodkin, D. A., Locatelli, F., Fukuhara, S., Young, E. W., Kurokawa, K., Saito, A., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00072.x · Cited by 858
Chau, I., Norman, A. R., Cunningham, D., Waters, J. S., Oates, J., & Ross, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.154 · Cited by 524
Maione, P., Perrone, F., Gallo, C., Manzione, L., Piantedosi, F., Barbera, S., Cigolari, S., Rosetti, F., Piazza, E., Robbiati, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.527 · Cited by 478
Loprinzi, C. L., Laurie, J. A., Wieand, H. S., Krook, J. E., Novotny, P. J., Kugler, J. W., Bartel, J., Law, M., Bateman, M., & Klatt, N. E. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.601 · Cited by 384
Lessons learned from measuring health-related quality of life in oncology.
Osoba, D. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.608 · Cited by 381
Cited by
Depression as a predictor of disease progression and mortality in cancer patients: A Meta‐Analysis
Satin, J. R., Linden, W., & Phillips, M. J. (2009) · Cancer · doi:10.1002/cncr.24561 · Cited by 972
“In a recent review of the prognostic significance of patientreported outcomes in cancer clinical trials, quality of life was shown to commonly predict survival perhaps even better than performance status.(85) Because the latter review was not a meta-analysis and used different inclusion criteria, we cannot compare the…”
ResultExercise interventions on health-related quality of life for cancer survivors
Mishra, S. I., Scherer, R. W., Geigle, P. M., Berlanstein, D. R., Topaloglu, O., Gotay, C. C., & Snyder, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007566.pub2 · Cited by 808
Self-citationEarly palliative care for adults with advanced cancer
Haun, M. W., Estel, S., Rücker, G., Friederich, H.-C., Villalobos, M., Thomas, M., & Hartmann, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011129.pub2 · Cited by 757
Mishra, S. I., Scherer, R. W., Snyder, C., Geigle, P. M., Berlanstein, D. R., & Topaloglu, O. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008465.pub2 · Cited by 679
Quinten, C., Coens, C., Mauer, M., Comte, S., Sprangers, M. A., Cleeland, C., Osoba, D., Bjordal, K., & Bottomley, A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70200-1 · Cited by 659
Self-citationvan den Bent, M., Wefel, J., Schiff, D., Taphoorn, M., Jaeckle, K., Junck, L., Armstrong, T., Choucair, A., Waldman, A., Gorlia, T., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70057-2 · Cited by 645
Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M., Appawu, M., Iasonos, A., Atkinson, T., Goldfarb, S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp386 · Cited by 624
Montazeri, A. (2009) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-7-102 · Cited by 568
Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4869 · Cited by 501
RETRACTED ARTICLE: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis
Liang, Y., Song, X., Li, Y., Chen, B., Zhao, W., Wang, L., Zhang, H., Liu, Y., Han, D., Zhang, N., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01206-5 · Cited by 373
RetractedAtkinson, T. M., Ryan, S. J., Bennett, A. V., Stover, A. M., Saracino, R. M., Rogak, L. J., Jewell, S. T., Matsoukas, K., Li, Y., & Basch, E. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3297-9 · Cited by 370
Ballesta, A., Innominato, P. F., Dallmann, R., Rand, D. A., & Lévi, F. A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013441 · Cited by 339
S3-Leitlinie „Magenkarzinom” -
Moehler, M., Al-Batran, S.-E., Andus, T., Anthuber, M., Arends, J., Arnold, D., Aust, D., Baier, P., Baretton, G., Bernhardt, J., et al. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0031-1273201 · Cited by 283
Snyder, C. F., Jensen, R. E., Segal, J. B., & Wu, A. W. (2013) · Medical Care · doi:10.1097/mlr.0b013e31829b1d84 · Cited by 258
Quality of life in adults with brain tumors: Current knowledge and future directions
Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-093 · Cited by 252
Brisbois, T. D., de Kock, I. H., Watanabe, S. M., Mirhosseini, M., Lamoureux, D. C., Chasen, M., MacDonald, N., Baracos, V. E., & Wismer, W. V. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq727 · Cited by 246
Symptom Burden in the First Year After Cancer Diagnosis: An Analysis of Patient-Reported Outcomes
Bubis, L. D., Davis, L., Mahar, A., Barbera, L., Li, Q., Moody, L., Karanicolas, P., Sutradhar, R., & Coburn, N. G. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0876 · Cited by 187
Innominato, P. F., Spiegel, D., Ulusakarya, A., Giacchetti, S., Bjarnason, G. A., Lévi, F., & Palesh, O. (2015) · Sleep Medicine · doi:10.1016/j.sleep.2014.10.022 · Cited by 88
“Nonetheless, other patientreported symptoms have been more extensively studied and their importance as independent prognostic factors in various cancers, including advanced colorectal cancer, has been confirmed [1,17–22].”
BackgroundLloyd, S., Baraghoshi, D., Tao, R., Garrido-Laguna, I., Gilcrease, G. W., Whisenant, J., Weis, J. R., Scaife, C., Pickron, T. B., Huang, L. C., et al. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000529 · Cited by 62
Putting patient-reported outcomes on the ‘Big Data Road Map’.
Calvert, M., Thwaites, R., Kyte, D., & Devlin, N. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076815579896 · Cited by 52
“Where PRO data may be used as an outcome in prognostic models to predict those patients most likely to obtain health gains and at an individual level to identify those who are a priority for care.(13) .”
MethodCohen, A. B., & Mathews, S. C. (2018) · Digital Biomarkers · doi:10.1159/000492396 · Cited by 24
Bennett, C., Doub, T., Bragg, A., Luellen, J., Regenmorter, C. V., Lockman, J., & Reiserer, R. (2011) · 2011 IEEE First International Conference on Healthcare Informatics, Imaging and Systems Biology · doi:10.1109/hisb.2011.20 · Cited by 20
“Research has begun to illuminate their utility on the effectiveness of clinical treatment across multiple disorders and diseases, including depression, schizophrenia, diabetes, cancer, and speech problems, among others [1-5].”
BackgroundDavis, L. E., Gupta, V., Allen-Ayodabo, C., Zhao, H., Hallet, J., Mahar, A. L., Ringash, J., Doherty, M., Kidane, B., Darling, G., et al. (2020) · Diseases of the Esophagus · doi:10.1093/dote/doz108 · Cited by 14
Living with Metastatic Breast Cancer
Ganz, P. A., & Stanton, A. L. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-16366-6_16 · Cited by 15
Metadata
- Authors
- Gotay, C. C., Kawamoto, C. T., Bottomley, A., & Efficace, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-03-10
- Volume
- 26
- Issue
- 8
- Pages
- 1355-1363
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002330540
- Cited by
- 644
- References
- 60
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.